CONNECT WITH US
Fintech

Fintech

Anthropic Buys One-Person Biotech to Prove Claude Can Make Drugs

PYMNTS – Fintech logo

Published on

Add as a preferred source on Google
Anthropic Buys One-Person Biotech to Prove Claude Can Make Drugs

Anthropic bought Mithril Medicine, a biotech with one full-time employee. He used Claude to run experiments across 11 contract labs and took a muscular dystrophy treatment from idea to mouse results in under 18 months.

OpenAI agreed to buy Orchestra Bio, which sells AI agents that track drug program timelines. When a manufacturing batch fails, the agents work out which trial dates slip and what the team can do about it.

Enveda used Claude to review the manufacturing records a drugmaker files before a trial, cutting the job from almost 26 hours to just under three. PYMNTS Intelligence found 84% of healthcare firms expect to increase AI spending over the next 12 months.

Anthropic said Oct. 27 it acquired Mithril Medicine, a startup developing treatments for two rare forms of muscular dystrophy. Founder Cody Tranbarger, Mithril’s only full-time employee, used Claude to organize contracts, logistics and experiments across 11 external labs and delegated other parts of the business to the model. Mithril took one candidate from idea to promising results in mice in under 18 months.

Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

Running real drug programs shows Anthropic where Claude holds up and where it fails, the company said. The programs also give it case studies to share with other biotechs, and medicines of its own if the candidates work. Tranbarger has joined the company and plans to start several more programs.


Source link
Related Topics:Fintech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.